Variants in STING1 have been linked to cervical cancer development (28), while in patients with metastatic colorectal cancer treated with cetuximab-based first-line therapy, IFNB1 rs1051922 correlates with progression-free survival (29). This evidence concerns the gene STING1 and metastatic colorectal cancer.